19,800 Shares in Pfizer Inc. $PFE Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,800 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

Other institutional investors have also recently made changes to their positions in the company. Grey Fox Wealth Advisors LLC purchased a new stake in Pfizer during the third quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new position in Pfizer in the 2nd quarter valued at approximately $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter worth $32,000. Evelyn Partners Asset Management Ltd bought a new position in shares of Pfizer in the second quarter worth $33,000. Finally, True Wealth Design LLC raised its stake in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $27.61 on Friday. The firm has a fifty day simple moving average of $26.13 and a two-hundred day simple moving average of $25.41. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The company has a market capitalization of $156.97 billion, a PE ratio of 20.30 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the company earned $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer’s dividend payout ratio is presently 126.47%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Wall Street Analyst Weigh In

A number of research firms have weighed in on PFE. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Bank of America decreased their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $27.70.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.